Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NovoCure Limited - Ordinary Shares (NQ:NVCR)

17.89 -0.68 (-3.63%)
Streaming Delayed Price Updated: 11:02 AM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
4 Analysts Have This to Say About NovoCure
Via Benzinga
Should You Buy Novocure Stock Right Now?
Most Wall Street analysts think this stock will skyrocket. They could be right. 
Via The Motley Fool
NovoCure (NVCR) Q1 2023 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Novocure Stock Dips As Q1 Earnings Miss Estimates, Higher Costs Hurt Bottom Line
Via Benzinga
NovoCure: Q1 Earnings Insights
Via Benzinga
Novocure Reports First Quarter 2023 Financial Results
From Novocure
Via Business Wire
What 4 Analyst Ratings Have To Say About NovoCure
Via Benzinga
2 Best Defensive Stocks to Buy in March
These two defensive stocks should shine in the event of a marketwide correction. 
Via The Motley Fool
NovoCure Earnings Perspective: Return On Capital Employed
Via Benzinga
Why NovoCure Stock Is Falling Today
Investors were looking for a stronger Q4 from the cancer company. 
Via The Motley Fool
The 3 Most Promising Healthcare Tech Stocks for April 2023
The best healthcare tech stocks provide investors with impressive upside potential, while promising to improve the healthcare sector. 
Via InvestorPlace
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Novocure
Via Business Wire
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
From Novocure
Via Business Wire
Novocure to Report First Quarter 2023 Financial Results
From Novocure
Via Business Wire
NovoCure (NVCR) Q4 2022 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Kristin Stafford Joins Novocure Board of Directors
From Novocure
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Why Novocure Stock Was so Healthy Today
There was good news from the laboratory on Hump Day. 
Via The Motley Fool
Why Novocure Stock Is Sliding Today
Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs. 
Via The Motley Fool
2 Stocks That Could Rebound and Rise 30% or More in 2023
They're down, but they aren't yet out. 
Via The Motley Fool
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Will Novocure Stock Sink or Soar in 2023?
The stock has both soared and sank already this year. 
Via The Motley Fool
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
From Novocure
Via Business Wire
Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes
A series of unexpected C-suite changes sent shares diving again. 
Via Investor's Business Daily
Novocure Announces Organizational Changes to Prepare for Future Growth
From Novocure
Via Business Wire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.